IOVA on Nasdaq
American biopharmaceutical startup
Iovance Biotherapeutics, Inc. is a biopharmaceutical company based in Philadelphia, Pennsylvania.3 From Wikipedia, CC BY-SA 4.0
Price unavailable
Last updated Oct 19, 2026.
Compare with Vericel, Adaptive Biotechnologies or Vaxart, or pick any stock.
See how the biggest companies compare on our leaderboards
Iovance Biotherapeutics, Inc. is a biopharmaceutical company based in Philadelphia, Pennsylvania. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.3
From the company’s reports to the SEC. Every number links to the filing it came from.
Revenue by product, business segment and region, as the company reports it to the SEC.
Amtagvi brought in 83% of the revenue Iovance Biotherapeutics broke down this way in fiscal 2025.
| Products and services | 2023 | 2024 | 2025 |
|---|---|---|---|
| Amtagvi | $103.6M | $220.0M | |
| Proleukin | $1.2M | $60.5M | $43.5M |
United States brought in 98% of the revenue Iovance Biotherapeutics broke down this way in fiscal 2025.
| Regions | 2023 | 2024 | 2025 |
|---|---|---|---|
| United States | $161.0M | $259.0M | |
| Outside the United States | $1.2M | $3.0M | $4.5M |
Out of $263.5M in revenue.8 The company lost money this year.
Every line of the income statement as filed: the last 3 fiscal years, latest first.8
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Total revenue | $263.5M | $164.1M | $1.2M |
| Cost of sales | $173.2M | $93.2M | $1.0M |
| Research and development | $300.3M | $276.2M | $333.2M |
| Selling, general, and administrative | $152.3M | $152.3M | $106.1M |
| Depreciation and amortization | $35.9M | $37.6M | $21.4M |
| Restructuring charges | $5.1M | ||
| Total costs and expenses | $666.9M | $559.3M | $461.7M |
| Loss from operations | -$403.4M | -$395.3M | -$460.6M |
| Interest and other income, net | $10.3M | $20.3M | $13.0M |
| Net Loss before income taxes | -$393.0M | -$375.0M | -$447.5M |
| Income tax (expense) benefit | $2.1M | $2.8M | $3.5M |
| Net Loss | -$391.0M | -$372.2M | -$444.0M |
| Net Loss Per Share of Common Stock, Basic (in dollars per share) | -$1.09 | -$1.28 | -$1.89 |
| Net Loss Per Share of Common Stock, Diluted (in dollars per share) | -$1.09 | -$1.28 | -$1.89 |
| Weighted Average Shares of Common Stock Outstanding, Basic (in shares) | 357.3K shares | 289.9K shares | 235.1K shares |
| Weighted Average Shares of Common Stock Outstanding, Diluted (in shares) | 357.3K shares | 289.9K shares | 235.1K shares |
| Non-cash stock-based compensation included in cost of sales | $7.3M | $8.6M | |
| Non-cash stock-based compensation included in research and development | $27.0M | $49.3M | $34.9M |
| Non-cash stock-based compensation included in selling, general and administrative | $27.3M | $51.8M | $27.7M |
| Share-based Compensation | $61.6M | $109.6M | $62.6M |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.8
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $163.1M | $115.7M | $114.9M | |
| Trade accounts receivable | $82.4M | $69.3M | ||
| Short-term investments | $133.9M | $208.1M | ||
| Inventory | $51.7M | $51.5M | ||
| Prepaid expenses and other assets | $11.6M | $12.4M | ||
| Total Current Assets | $442.7M | $457.0M | ||
| Property and equipment, net | $131.1M | $109.1M | ||
| Intangible assets, net | $279.3M | $282.4M | ||
| Operating lease right-of-use assets | $45.9M | $55.2M | ||
| Restricted cash | $6.0M | $6.4M | ||
| Long-term assets | $8.2M | $369.0K | ||
| Total Assets | $913.2M | $910.4M | ||
| Accounts payable | $22.2M | $27.5M | ||
| Accrued expenses and other liabilities | $111.2M | $81.9M | ||
| Note payable - current | $1.0M | |||
| Operating lease liabilities | $4.0M | $12.9M | ||
| Total Current Liabilities | $138.4M | $122.3M | ||
| Operating lease liabilities - non-current | $44.4M | $44.4M | ||
| Deferred tax liabilities | $31.8M | $32.3M | ||
| Long-term note payable | $1.0M | |||
| Total Non-Current Liabilities | $76.2M | $77.7M | ||
| Total Liabilities | $214.6M | $200.0M | ||
| Common stock, $0.000041666 par value; 500,000,000 shares authorized, 411,938,061 and 305,252,194 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively | $17.0K | $13.0K | ||
| Accumulated other comprehensive income (loss) | $16.4M | -$1.0M | ||
| Additional paid-in capital | $3.5B | $3.1B | ||
| Accumulated deficit | -$2.8B | -$2.4B | ||
| Total Stockholders' Equity | $698.6M | $710.4M | $584.6M | $499.6M |
| Total Liabilities and Stockholders' Equity | $913.2M | $910.4M | ||
| Common stock, par or stated value per share | $0.00 | $0.00 | ||
| Common stock, shares authorized | 500.0M shares | 500.0M shares | ||
| Common Stock, Shares, Issued | 411.9M shares | 305.3M shares | ||
| Common Stock, Shares, Outstanding | 411.9M shares | 305.3M shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $163.1M | $115.7M | $114.9M | |
| Trade accounts receivable | $82.4M | $69.3M | ||
| Short-term investments | $133.9M | $208.1M | ||
| Inventory | $51.7M | $51.5M | ||
| Prepaid expenses and other assets | $11.6M | $12.4M | ||
| Total Current Assets | $442.7M | $457.0M | ||
| Property and equipment, net | $131.1M | $109.1M | ||
| Intangible assets, net | $279.3M | $282.4M | ||
| Operating lease right-of-use assets | $45.9M | $55.2M | ||
| Restricted cash | $6.0M | $6.4M | ||
| Long-term assets | $8.2M | $369.0K | ||
| Total Assets | $913.2M | $910.4M | ||
| Accounts payable | $22.2M | $27.5M | ||
| Accrued expenses and other liabilities | $111.2M | $81.9M | ||
| Note payable - current | $1.0M | |||
| Operating lease liabilities | $4.0M | $12.9M | ||
| Total Current Liabilities | $138.4M | $122.3M | ||
| Operating lease liabilities - non-current | $44.4M | $44.4M | ||
| Deferred tax liabilities | $31.8M | $32.3M | ||
| Long-term note payable | $1.0M | |||
| Total Non-Current Liabilities | $76.2M | $77.7M | ||
| Total Liabilities | $214.6M | $200.0M | ||
| Common stock, $0.000041666 par value; 500,000,000 shares authorized, 411,938,061 and 305,252,194 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively | $17.0K | $13.0K | ||
| Accumulated other comprehensive income (loss) | $16.4M | -$1.0M | ||
| Additional paid-in capital | $3.5B | $3.1B | ||
| Accumulated deficit | -$2.8B | -$2.4B | ||
| Total Stockholders' Equity | $698.6M | $710.4M | $584.6M | $499.6M |
| Total Liabilities and Stockholders' Equity | $913.2M | $910.4M | ||
| Common stock, par or stated value per share | $0.00 | $0.00 | ||
| Common stock, shares authorized | 500.0M shares | 500.0M shares | ||
| Common Stock, Shares, Issued | 411.9M shares | 305.3M shares | ||
| Common Stock, Shares, Outstanding | 411.9M shares | 305.3M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 3 fiscal years, latest first.8
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net loss | -$391.0M | -$372.2M | -$444.0M |
| Stock-based compensation expense | $61.6M | $109.6M | $62.6M |
| Unrealized foreign exchange loss | -$238.0K | -$175.0K | $70.0K |
| Amortization of intangible assets | $23.1M | $26.4M | $9.8M |
| Amortization of right of use asset | $11.4M | $10.4M | $11.7M |
| Depreciation and amortization of property and equipment | $12.9M | $11.3M | $11.6M |
| Deferred tax (benefit) expense | -$2.1M | -$2.8M | -$3.5M |
| Excess and obsolescence reserve | $13.4M | ||
| Accretion of discounts and premiums on investments | -$7.2M | -$10.3M | -$3.6M |
| Loss on asset disposals | $44.0K | $7.4M | |
| Gain on derecognition of lease assets and liabilities | -$5.6M | ||
| Prepaid expenses, other assets and long-term assets | -$8.0M | -$2.1M | -$10.1M |
| Trade accounts receivable | -$13.1M | -$69.2M | -$149.0K |
| Inventory | -$14.2M | -$44.4M | -$10.1M |
| Operating lease liabilities | -$10.9M | -$12.1M | -$10.8M |
| Accounts payable | -$6.7M | -$7.8M | $4.8M |
| Accrued expenses and other liabilities | $28.6M | $8.6M | $19.8M |
| Net cash used in operating activities | -$302.4M | -$353.0M | -$361.8M |
| Maturities of investments | $400.0M | $428.0M | $285.6M |
| Purchase of investments | -$318.7M | -$460.8M | -$205.9M |
| Cash paid for acquisition, including contingent consideration, net of cash acquired | -$52.6M | -$212.6M | |
| Purchase of property and equipment | -$33.8M | -$11.1M | -$22.3M |
| Net cash provided by (used in) investing activities | $47.5M | -$96.4M | -$155.2M |
| Tax payments related to shares withheld for vested restricted stock units | -$7.1M | -$12.9M | -$2.8M |
| Proceeds from the issuance of common stock under employee stock purchase plan | $1.5M | $3.0M | $2.4M |
| Proceeds from the issuance of common stock upon exercise of options | $15.0K | $3.3M | $63.0K |
| Proceeds from the issuance of common stock, net | $306.3M | $397.3M | $463.3M |
| Net cash provided by financing activities | $300.8M | $390.7M | $463.0M |
| Effect of foreign exchange rate changes | $1.1M | -$541.0K | -$2.7M |
| Net increase (decrease) in cash, cash equivalents and restricted cash | $47.0M | -$59.3M | -$56.8M |
| Fair value of net assets acquired | $222.6M | ||
| Net unrealized loss on investments | $54.0K | $78.0K | $940.0K |
| Acquisition of property and equipment included in accounts payable and accrued expenses | $8.5M | $7.4M | $4.1M |
| Intangible asset and deferred tax liability arising from contingent consideration | $17.5M | ||
| Conversion of convertible preferred stock to common stock | $1.0K | ||
| Lease liabilities arising from obtaining right-of-use asset from new leases | $2.3M | $177.0K | |
| Increase / (decrease) in lease liabilities due to obtaining/(reduction in) right-of-use assets from lease modifications | $2.1M | -$7.8M | $1.0M |
No quarter-by-quarter statement was filed.
The company was founded in 2007 as Genesis Biopharma. In 2013, Lion merged with Genesis Biopharma аnd became Lion Bio Pharma, which was then rebranded to Iovance in 2017.
In 2024, the US FDA gave accelerated approval to Lifileucel, marketed under the brand name Amtagvi, the company's tumor-infiltrating lymphocyte drug for the treatment of unresectable or metastatic melanoma.
From Wikipedia’s article on Iovance Biotherapeutics, shared under CC BY-SA 4.0.6
Who has led Iovance Biotherapeutics, and when. Pick a name to see everywhere that person has worked.
362 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 80 major events, 183 insider forms, 35 large holders, 44 other. The latest 20:
The 362 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
21 open-market trades by officers, directors and large owners since October 2021: 20 buys and 1 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Jun 5, 2025 | Kirby Daniel GordonChief Commercial Officer | Buy | 30,000 | $1.84 | $55.2K | Form 4 |
| May 23, 2025 | Puri Raj K.Chief Regulatory Officer | Buy | 5,600 | $1.74 | $9.7K | Form 4 |
| May 14, 2025 | Vogt Frederick GInterim CEO & General Counsel | Buy | 25,000 | $1.69 | $42.2K | Form 4 |
| Nov 12, 2024 | Maynard Ryan DDirector | Sale | 50,000 | $10.06 | $503.0K | Form 4 |
| Feb 20, 2024 | MCPEAK MERRILL ADirector | Buy | 250,000 | $9.15 | $2.3M | Form 4 |
| Feb 20, 2024 | Dukes Iain D.Director | Buy | 32,000 | $9.15 | $292.8K | Form 4 |
| Feb 20, 2024 | Rothbaum Wayne P.Director | Buy | 5,000,000 | $9.15 | $45.8M | Form 4 |
| Sep 18, 2023 | MCPEAK MERRILL ADirector | Buy | 10,000 | $5.56 | $55.6K | Form 4 |
| Sep 15, 2023 | Rothbaum Wayne P.Director | Buy | 5,000,000 | $5.30 | $26.5M | Form 4 |
| Dec 21, 2022 | MCPEAK MERRILL ADirector | Buy | 10,000 | $6.15 | $61.5K | Form 4 |
| Dec 2, 2022 | Rothbaum Wayne P.Director | Buy | 10,000,000 | $6.50 | $65.0M | Form 4 |
| Nov 29, 2022 | MCPEAK MERRILL ADirector | Buy | 10,000 | $6.31 | $63.1K | Form 4 |
| Nov 28, 2022 | Vogt Frederick GInterim CEO & General Counsel | Buy | 1,000 | $5.98 | $6.0K | Form 4 |
| Nov 28, 2022 | MCPEAK MERRILL ADirector | Buy | 10,000 | $6.18 | $61.8K | Form 4 |
| Nov 23, 2022 | Dukes Iain D.Director | Buy | 10,000 | $6.10 | $61.0K | Form 4 |
| Jun 1, 2022 | Vogt Frederick GInterim CEO & General Counsel | Buy | 1,000 | $6.44 | $6.4K | Form 4 |
| Jun 1, 2022 | Rothbaum Wayne P.Director | Buy | 500,000 | $6.43 | $3.2M | Form 4 |
| May 31, 2022 | MCPEAK MERRILL ADirector | Buy | 20,000 | $6.82 | $136.4K | Form 4 |
| May 31, 2022 | Maynard Ryan DDirector | Buy | 7,500 | $6.75 | $50.6K | Form 4 |
| May 31, 2022 | WEISER MICHAELDirector | Buy | 10,000 | $6.80 | $68.0K | Form 4 |
All 21 trades can be filtered by person here when JavaScript is on.
From Forms 4 filed with the SEC.
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.
| Fund | Shares | Value | Share of the fund | Change |
|---|---|---|---|---|
| BlackRock, Inc. | 36,957,681 | $153.7M | 0.0% | +5,877,176 |
| Mhr Fund Management LLC | 28,967,103 | $120.5M | 6.3% | No change |
| State Street Corp | 24,478,268 | $101.8M | 0.0% | +7,030,160 |
| Two Sigma Investments, LP | 19,010,697 | $79.1M | 0.1% | +5,323,264 |
| Vanguard Capital Management LLC | 18,204,248 | $75.7M | 0.0% | +1,586,511 |
| Vanguard Portfolio Management LLC | 14,388,999 | $59.9M | 0.0% | +2,688,155 |
| Geode Capital Management, LLC | 10,324,826 | $43.0M | 0.0% | +1,752,228 |
| Millennium Management LLC | 8,525,919 | $35.5M | 0.0% | −888,373 |
| Dimensional Fund Advisors LP | 6,460,449 | $26.9M | 0.0% | +3,814,747 |
| Palo Alto Investors LP | 5,296,209 | $22.0M | 3.0% | −1,053,354 |
| Goldman Sachs Group Inc | 5,096,334 | $21.2M | 0.0% | −3,663,726 |
| Nuveen, LLC | 4,997,112 | $20.8M | 0.0% | +1,332,834 |
| Bank Of America Corp /de/ | 4,993,584 | $20.8M | 0.0% | −3,496,535 |
| Morgan Stanley | 4,986,461 | $20.7M | 0.0% | −1,214,821 |
| Jupiter Asset Management Ltd | 4,535,080 | $18.9M | 0.1% | New |
| Jane Street Group, LLC | 4,393,853 | $18.3M | 0.0% | +219,967 |
| Northern Trust Corp | 4,154,200 | $17.3M | 0.0% | +1,278,674 |
| Aqr Capital Management LLC | 3,869,584 | $16.1M | 0.0% | +3,245,416 |
| Wells Fargo & Company/mn | 3,246,537 | $13.5M | 0.0% | +1,175,013 |
| Charles Schwab Investment Management Inc | 3,219,656 | $13.4M | 0.0% | +435,926 |
| Susquehanna International Group, Llp | 2,656,740 | $11.1M | 0.0% | −340,003 |
| Vanguard Fiduciary Trust Co | 2,542,878 | $10.6M | 0.0% | +358,580 |
| Jpmorgan Chase & Co | 2,431,616 | $10.2M | 0.0% | −69,008 |
| D. E. Shaw & Co., Inc. | 2,143,134 | $8.9M | 0.0% | −5,873,219 |
| Citadel Advisors LLC | 2,104,990 | $8.8M | 0.0% | −506,355 |
13F reports cover disclosed long positions in U.S. stocks only.
The numbers on this page point here. Each one links to the record it came from.